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| WHAT IS KNOWN AND OBJECTIVE
Neuroleptic malignant syndrome (NMS) is a rare but severe adverse effect of antipsychotic drugs. NMS is characterized by hyperthermia and muscle rigidity, and at least two of the following symptoms: change in mental status, hypertension, tachycardia, shaking, incontinence, or creatine kinase (CK) increase and/or leukocytosis.
1 Furthermore during heatwave, neuroleptics (NL) may affect the body's thermoregulation. 2 Despite a large use of antipsychotics, this syndrome is rarely 
| CASE DESCRIPTION
Patient A was a 49-year-old man with a body mass index (BMI) of (Table 1) . Elevated levels of leukocytosis (12 800 g/L) and CK (562 UI/L) were found at admission (Table 2) Both cases were reviewed by the expert committee and were reported to the regional pharmacovigilance centre. According to studies, major criteria were hyperthermia, rigidity and/ or extrapyramidal symptoms, and minor criteria were altered consciousness, tachycardia, hypertension, tachypnoea, diaphoresis and leukocytosis. 15, 16 For some studies, elevated CPK was a major 15 or a minor 16 criteria for NMS diagnosis. Furthermore, the level of CPK in the NMS diagnosis is not clearly established [16] [17] [18] and differs between studies. 15, 19 A large number of cases published did not mention the criteria used to diagnose NMS. 13 Our two cases presented two major (hyperthermia and rigidity) and three minor (altered consciousness, hypertension and tachycardia) criteria of NMS. In addition, our two cases had increased CK and myoglobin levels. Moreover, these results and the absence of a differential diagnosis allowed us to establish the diagnosis of NMS. In addition, we observed that patient B, who presented with more severe criteria for NMS compared with patient A, also showed a greater clinical severity resulting in the death of the patient. One hypothesis may be that patient A was at the beginning of the NMS and presented less risk factors. However, NMS has a low incidence (0.02%-2.4% of the patients treated by antipsychotics) but may have a fatal outcome (10%-50%). 
| WHAT IS NEW AND CONCLUSION

| CONCLUSION
In the ED, clinical pharmacists have an important role. They can implement activities such as medication history, medication reconciliation or research of iatrogenic events, facilitating rapid and appropriate medical care and raising awareness of medical teams about iatrogenic events.
13
To conclude, medical and pharmaceutical teams must keep in mind that NMS is a rare pathological state but a potentially fatal adverse effect of NL drugs. It is not easily distinguishable from malignant hyperthermia during high heat. At-risk subjects must be identified, and their treatment must be evaluated and monitored to maintain a benefit-risk balance. Symptoms suggesting NMS must be rapidly identified, in particular during heatwave periods.
